# Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

> **NCT03249506** · — · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 25358 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Empagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Dipeptidyl Peptidase-4 Inhibitor (DPP-4)
- **DRUG:** Glucagon-Like Peptide-1 Agonist (GLP-1)
- **DRUG:** Thiazolidinedione (TZD)
- **DRUG:** Sulfonylureas
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT03249506
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-12
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 25358 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03249506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03249506, "Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03249506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*